Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that it will debut its OncAlert™ Oral Cancer product line in Hall 4.2 Booth #N049 at the International Dental Show (IDS) 2015, the world’s leading tradeshow for the dental industry, being held March 10-14, 2015 in Cologne, Germany.
Additionally, Vigilant’s Chief Dental Officer, John Comisi, DDS, MAGD, will present an oral presentation, “Improving Early Detection of Oral Cancer with Salivary Diagnostics,” on Thursday, March 12th at 10:00 a.m. in Speakers‘ Corner, Hall 3.1 M010, at IDS.
Vigilant Biosciences’ initial products, the OncAlert Oral Cancer RAPID Test (“OncAlert RAPID Test”) and the OncAlert Oral Cancer LAB Test (“OncAlert LAB Test”), are the first and only technologies that measure soluble CD44 and total protein levels – protein markers clinically shown to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. Both products use a simple, oral rinse collection and measurement procedure that is easy to administer and non-invasive for the patient. The accurate, cost-effective tests can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus). The OncAlert LAB Test is CE Marked. The OncAlert RAPID Test is currently undergoing the CE Mark registration process and not yet available for sale in any market at this time. The OncAlert Oral Cancer product line is not yet available for sale in the U.S.
“We are thrilled to be making our global debut of the OncAlert product line at IDS, and look forward to completing our CE Mark registration and launching our product line in Europe,” said Matthew H.J. Kim, Founder, Chairman, and CEO of Vigilant Biosciences. “As hundreds of thousands continue to be diagnosed with oral cancer every year, our simple, specific and affordable test can aid in earlier detection and intervention of this disease. We are committed to working with dental professionals around the world to incorporate this test seamlessly into their standard practice.”
“As a practicing dental professional, I’ve seen firsthand the impact that oral cancer can have when detected at a late stage,” said Dr. John Comisi, Chief Dental Officer of Vigilant Biosciences. “The OncAlert system will elevate the standard of care and transform the detection of oral cancer by providing a very simple and very specific method to help aid in the detection of oral cancer. It’s non-invasive and takes only seconds to administer with the rapid test providing results in minutes, making it easy to incorporate into a routine exam.”
About Oral Cancer
According to the Oral Cancer Foundation, there are over 640,000 new cases of oral cancer each year worldwide. In the U.S., close to 48,250 individuals will be diagnosed with oral or pharyngeal cancer this year, with 9,575 deaths from the disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early diagnosis of oral cancer results in a cure rate of up to 90 percent.
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. Vigilant’s OncAlert Oral Cancer product line includes rapid and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The OncAlert Oral Cancer product line is not yet available for sale in the U.S. For more information, visit www.vigilantbiosciences.com.